bicavera 4,25 % glucose, 1,75 mmol/l calcium roztok pro peritoneální dialýzu
fresenius medical care deutschland gmbh, bad homburg array - 1322 chlorid sodnÝ; 235 chlorid vÁpenatÝ; 856 hexahydrÁt chloridu hoŘeČnatÉho; 4957 monohydrÁt glukosy; 2178 hydrogenuhliČitan sodnÝ - roztok pro peritoneální dialýzu - hypertonickÉ roztoky
zinkorot 25mg tableta
wörwag pharma gmbh & co. kg, böblingen array - 13347 dihydrÁt zinkum-orotÁtu - tableta - 25mg - zinek
prodigestan perorální prášek
tekro spol. s r.o. - propionát sodný, kombinace - perorální prášek - léky pro prevenci a nebo léčbu acetonemii - kozy, prasata, ovce, skot, psi
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologické látky - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologické látky - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologické látky - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
herbion pastilka
krka, d.d., novo mesto, novo mesto array - 16874 suchÝ extrakt z bŘeČtanovÉho listu - pastilka - bŘeČŤanovÝ list
recudon 5 + 0,25 mg/ml injekční roztok
alfasan nederland bv - metadon, kombinace bez dph. psycholeptics - injekční roztok - diphenylpropylamine deriváty - koně, psi
recudon 2,5 + 0,125 mg/ml injekční roztok
alfasan nederland bv - metadon, kombinace bez dph. psycholeptics - injekční roztok - diphenylpropylamine deriváty - koně, psi
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologické látky - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.